Welcome to our dedicated page for McKesson Corporation news (Ticker: MCK), a resource for investors and traders seeking the latest updates and insights on McKesson Corporation stock.
McKesson Corporation (symbol: MCK) is a leading healthcare services and information technology company, dedicated to improving the business of healthcare globally. Ranked 11th on the Fortune 500 list, McKesson collaborates with a diverse range of stakeholders including payers, hospitals, physician offices, pharmacies, pharmaceutical companies, and other entities across the healthcare spectrum. The company's mission is to foster healthier organizations that deliver superior care to patients in every setting.
McKesson is one of the top three pharmaceutical wholesalers in the United States, engaging in the sourcing and distribution of branded, generic, and specialty pharmaceutical products. Their extensive client base includes retail chains, independent pharmacies, mail-order pharmacies, hospital networks, and healthcare providers. Alongside Cencora and Cardinal Health, McKesson commands over 90% of the US pharmaceutical wholesale industry.
Beyond the US, McKesson's reach extends to Canada, where they are involved in pharmaceutical wholesale and distribution. Additionally, McKesson supplies medical-surgical products and equipment to healthcare facilities and offers a range of technology solutions tailored for pharmacies.
McKesson's comprehensive service offerings include pharmaceutical and medical-surgical supply management, healthcare information technology solutions, and business and clinical services. The company is committed to helping its customers enhance their financial, operational, and clinical performance, ultimately aiming to deliver better patient care.
Recent achievements include strategic partnerships and innovative projects that continue to position McKesson as a key player in the healthcare industry. Their ongoing projects are designed to streamline operations and improve efficiency across the board, ensuring that healthcare providers can focus on patient care.
For more details on McKesson Corporation, visit www.mckesson.com.
On July 22, 2022, McKesson Corporation (NYSE:MCK) declared a regular dividend of $0.54 per share, marking a 15% increase from the previous $0.47. The dividend will be payable on October 3, 2022, to shareholders of record as of September 1, 2022. CEO Brian Tyler emphasized the dividend increase reflects robust cash flow and the company’s confidence in its long-term growth strategy. Notably, this marks the sixth consecutive year of dividend increases for McKesson.
McKesson Corporation (NYSE: MCK) will announce its first quarter fiscal 2023 financial results on August 3, 2022, after market close. The company will conduct a live webcast at 4:30 PM Eastern Time to discuss the results. Investors can access the webcast and related financial documentation on the company’s Investor Relations website. McKesson is committed to improving health outcomes and providing affordable healthcare solutions through partnerships with various stakeholders in the healthcare sector.
McKesson Corporation and HCA Healthcare have announced a joint venture to combine their oncology research arms, US Oncology Research and Sarah Cannon Research Institute, enhancing clinical trial access and drug development. This venture aims to expand oncology research, streamline trial matching for patients, and improve access, particularly for underserved communities. McKesson will hold 51% ownership, with the joint venture expected to close in 2022. Financial details remain undisclosed, and the agreement is subject to regulatory approvals.
McKesson Corporation and HCA Healthcare have announced a joint venture to combine their oncology research efforts, enhancing clinical trials and treatment options for cancer patients. The venture will merge McKesson’s US Oncology Research with HCA’s Sarah Cannon Research Institute, aiming to improve access and accelerate cancer drug development, especially in underserved communities. McKesson will hold a 51% stake and operating control. The deal is expected to close in 2022, pending regulatory approval and customary conditions.
McKesson Corporation (NYSE: MCK) announced its fiscal 2022 fourth-quarter financial results, which are accessible through its Investor Relations website. A live webcast of the earnings conference call is scheduled for May 5 at 4:30 PM ET, allowing investors to review the results in detail. McKesson aims to enhance healthcare accessibility and affordability through partnerships with various healthcare entities. More information is available on their official website.
AmerisourceBergen (ABC), Cardinal Health (CAH), and McKesson (MCK) have settled opioid-related claims with the Washington Attorney General, agreeing to pay up to $518 million. This payment resolves lawsuits filed by the state and its subdivisions, allowing for the dismissal of ongoing litigation. The settlement aligns with a previously announced agreement effective April 2, 2022, aimed at addressing a significant portion of opioid claims against the distributors. The companies dispute the allegations but see this as steps toward broader resolutions and relief for impacted communities.
The Board of Directors of McKesson Corporation (NYSE:MCK) has declared a regular dividend of 47 cents per share of common stock. This dividend will be payable on July 1, 2022, to stockholders of record on June 1, 2022. McKesson Corporation is a leader in healthcare services, focusing on enhancing health outcomes through partnerships with various stakeholders in the industry, including biopharma companies and care providers. For further information, visit McKesson.com.
McKesson Corporation (NYSE: MCK) has successfully closed the sale of its UK businesses to AURELIUS, enhancing its focus on streamlining operations and exiting the European market.
The company is set to report its fourth quarter fiscal 2022 financial results on May 5, 2022, with a live earnings conference call at 4:30 PM ET. Further comments on the sale will be provided during this call, with the earnings release and financial details accessible on McKesson's Investor Relations website.
McKesson Corporation (NYSE: MCK) announced the election of W. Roy Dunbar as a new director and member of the Audit and Governance Committees, effective April 1, 2022. This expands the board from 11 to 12 members, with 11 being independent. Dunbar brings extensive experience from roles at Network Solutions, Mastercard, and Eli Lilly, focusing on technology, operations, and sustainability. His addition is expected to enhance the board's oversight, particularly in oncology, biopharma, data governance, and cybersecurity.
Settlement Announcement: AmerisourceBergen (ABC), Cardinal Health (CAH), and McKesson (MCK) have reached an agreement to settle the majority of opioid lawsuits with participation from 46 of 49 eligible states and over 90% of litigating political subdivisions. The settlement totals approximately $19.5 billion to be distributed over 18 years, with individual contributions of $6.1 billion, $6.0 billion, and $7.4 billion from AmerisourceBergen, Cardinal Health, and McKesson, respectively. The agreement aims to provide relief to communities affected by the opioid crisis.
FAQ
What is the current stock price of McKesson Corporation (MCK)?
What is the market cap of McKesson Corporation (MCK)?
What services does McKesson Corporation provide?
Where does McKesson Corporation operate?
Who are McKesson's primary clients?
What makes McKesson a leading pharmaceutical wholesaler?
How does McKesson help improve healthcare delivery?
What are some recent achievements of McKesson Corporation?
Can individuals buy products directly from McKesson?
How does McKesson contribute to the healthcare industry?
What is the significance of McKesson's partnerships?
Where can I find more information about McKesson Corporation?
